• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症患者的高凝状态、静脉血栓栓塞与死亡。一种多状态模型。

Hypercoagulabilty, venous thromboembolism, and death in patients with cancer. A Multi-State Model.

作者信息

Posch Florian, Riedl Julia, Reitter Eva-Maria, Kaider Alexandra, Zielinski Christoph, Pabinger Ingrid, Ay Cihan

机构信息

Dr. Cihan Ay, Medical University of Vienna, Department of Medicine I, Clinical Division of Haematology and Haemostaseology, Währinger Gürtel 18-20, 1090 Vienna, Austria, Tel.: +43 1 40400 4410, Fax: +43 1 40400 4030, E-mail:

出版信息

Thromb Haemost. 2016 Apr;115(4):817-26. doi: 10.1160/TH15-09-0758. Epub 2016 Jan 7.

DOI:10.1160/TH15-09-0758
PMID:26738412
Abstract

Venous thromboembolism (VTE) is a frequent complication of malignancy. The aim of this study was to investigate whether multi-state modelling may be a useful quantitative approach to dissect the complex epidemiological relationship between hypercoagulability, VTE, and death in cancer patients. We implemented a three-state/three-transition unidirectional illness-death model of cancer-associated VTE in data of 1,685 cancer patients included in a prospective cohort study, the Vienna Cancer and Thrombosis Study (CATS). During the two-year follow-up period, 145 (8.6 %) patients developed VTE, 79 (54.5 %) died after developing VTE, and 647 (38.4 %) died without developing VTE, respectively. VTE events during follow-up were associated with a three-fold increase in the risk of death (Transition Hazard ratio (HR)=2.98, 95 % confidence interval [CI]: 2.36-3.77, p< 0.001). This observation was independent of cancer stage. VTE events that occurred later during follow-up exerted a stronger impact on the risk of death than VTE events that occurred at earlier time points (HR for VTE occurrence one year after baseline vs at baseline=2.30, 95 % CI: 1.28-4.15, p=0.005). Elevated baseline D-dimer levels emerged as a VTE-independent risk factor for mortality (HR=1.07, 95 % CI: 1.05-1.08, p< 0.001), and also predicted mortality risk in patients who developed VTE. A higher Khorana Score predicted both the risk for VTE and death, but did not predict mortality after cancer-associated VTE. In conclusion, multi-state modeling represents a very potent approach to time-to-VTE cohort data in the cancer population, and should be used for both observational and interventional studies on cancer-associated VTE.

摘要

静脉血栓栓塞症(VTE)是恶性肿瘤常见的并发症。本研究旨在探讨多状态建模是否可能是一种有用的定量方法,以剖析癌症患者高凝状态、VTE和死亡之间复杂的流行病学关系。我们在一项前瞻性队列研究——维也纳癌症与血栓形成研究(CATS)纳入的1685例癌症患者的数据中,实施了癌症相关VTE的三状态/三转变单向疾病-死亡模型。在两年的随访期内,分别有145例(8.6%)患者发生VTE,79例(54.5%)在发生VTE后死亡,647例(38.4%)未发生VTE而死亡。随访期间的VTE事件与死亡风险增加三倍相关(转变风险比(HR)=2.98,95%置信区间[CI]:2.36-3.77,p<0.001)。这一观察结果与癌症分期无关。随访后期发生的VTE事件对死亡风险的影响比早期发生的VTE事件更强(基线后一年发生VTE与基线时发生VTE的HR=2.30,95%CI:1.28-4.15,p=0.005)。基线D-二聚体水平升高是与VTE无关的死亡风险因素(HR=1.07,95%CI:1.05-1.08,p<0.001),并且也预测了发生VTE患者的死亡风险。较高的科纳纳评分既预测了VTE风险也预测了死亡风险,但未预测癌症相关VTE后的死亡情况。总之,多状态建模是分析癌症人群VTE发生时间队列数据的一种非常有效的方法,应用于癌症相关VTE的观察性研究和干预性研究。

相似文献

1
Hypercoagulabilty, venous thromboembolism, and death in patients with cancer. A Multi-State Model.癌症患者的高凝状态、静脉血栓栓塞与死亡。一种多状态模型。
Thromb Haemost. 2016 Apr;115(4):817-26. doi: 10.1160/TH15-09-0758. Epub 2016 Jan 7.
2
Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS).平均血小板体积与癌症患者静脉血栓栓塞风险及死亡率的关联。维也纳癌症与血栓形成研究(CATS)的结果。
Thromb Haemost. 2014 Apr 1;111(4):670-8. doi: 10.1160/TH13-07-0603. Epub 2013 Dec 5.
3
D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.D-二聚体和凝血酶原片段1+2可预测癌症患者发生静脉血栓栓塞:来自维也纳癌症与血栓形成研究的结果。
J Clin Oncol. 2009 Sep 1;27(25):4124-9. doi: 10.1200/JCO.2008.21.7752. Epub 2009 Jul 27.
4
Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an observational cohort study.接受辅助化疗或主动监测的局限性结直肠癌患者静脉血栓栓塞风险模式:一项观察性队列研究
BMC Cancer. 2017 Jun 15;17(1):415. doi: 10.1186/s12885-017-3392-4.
5
Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients.癌症患者血清白蛋白降低与静脉血栓栓塞风险及死亡率之间的关联
Oncologist. 2016 Feb;21(2):252-7. doi: 10.1634/theoncologist.2015-0284. Epub 2016 Jan 13.
6
A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality.一种经过验证的静脉血栓栓塞风险评分可预测癌症进展和死亡率。
Oncologist. 2016 Jul;21(7):861-7. doi: 10.1634/theoncologist.2015-0361. Epub 2016 Apr 28.
7
Red cell distribution width and other red blood cell parameters in patients with cancer: association with risk of venous thromboembolism and mortality.癌症患者的红细胞分布宽度及其他红细胞参数:与静脉血栓栓塞风险和死亡率的关联
PLoS One. 2014 Oct 27;9(10):e111440. doi: 10.1371/journal.pone.0111440. eCollection 2014.
8
Family history of venous thromboembolism and mortality after venous thromboembolism: a Swedish population-based cohort study.静脉血栓栓塞的家族史与静脉血栓栓塞后的死亡率:一项基于瑞典人群的队列研究。
J Thromb Thrombolysis. 2017 May;43(4):469-475. doi: 10.1007/s11239-016-1464-y.
9
Venous Thromboembolism Is an Independent Predictor of Mortality Among Patients with Gastric Cancer.静脉血栓栓塞是胃癌患者死亡率的独立预测因素。
J Gastrointest Cancer. 2018 Dec;49(4):415-421. doi: 10.1007/s12029-017-9981-2.
10
Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study.晚期胰腺癌患者静脉血栓栓塞症的发病率、转归和风险分层工具 - 一项回顾性队列研究。
Thromb Res. 2017 Sep;157:9-15. doi: 10.1016/j.thromres.2017.06.021. Epub 2017 Jun 20.

引用本文的文献

1
Association between D-Dimer and Long-Term Major Adverse Cardiovascular Outcomes in Patients with Masked Hypertension.隐匿性高血压患者中D-二聚体与长期主要不良心血管事件的关联
Med Princ Pract. 2025 Apr 26:1-9. doi: 10.1159/000546076.
2
Early Change in C-Reactive Protein and Venous Thromboembolism in Patients Treated With Immune Checkpoint Inhibitors.接受免疫检查点抑制剂治疗患者的C反应蛋白早期变化与静脉血栓栓塞
JACC CardioOncol. 2024 Nov 12;6(6):965-975. doi: 10.1016/j.jaccao.2024.09.007. eCollection 2024 Dec.
3
Incidence, Risk Factors, and Modified Risk Assessment Model of Venous Thromboembolism in Non-Hodgkin Lymphoma Patients.
非霍奇金淋巴瘤患者静脉血栓栓塞的发病率、危险因素及改良风险评估模型
Cancer Med. 2024 Dec;13(24):e70510. doi: 10.1002/cam4.70510.
4
Cancer progression and tumor hypercoagulability: a platelet perspective.癌症进展与肿瘤高凝状态:血小板的视角。
J Thromb Thrombolysis. 2024 Aug;57(6):959-972. doi: 10.1007/s11239-024-02993-0. Epub 2024 May 17.
5
Association between D-dimer and long-term mortality in patients with acute severe hypertension visiting the emergency department.急诊科急性重症高血压患者D-二聚体与长期死亡率的关联
Clin Hypertens. 2023 Jun 15;29(1):16. doi: 10.1186/s40885-023-00244-7.
6
Hemostasis and cancer: Impact of haemostatic biomarkers for the prediction of clinical outcomes in patients with cancer.止血与癌症:止血生物标志物对癌症患者临床结局预测的影响。
J Thromb Haemost. 2022 Dec;20(12):2733-2745. doi: 10.1111/jth.15880. Epub 2022 Sep 27.
7
Prediction models for venous thromboembolism in ambulatory adults with pancreatic and gastro-oesophageal cancer: protocol for systematic review and meta-analysis.门诊成人胰腺和胃食管癌症患者静脉血栓栓塞预测模型:系统评价和荟萃分析的方案。
BMJ Open. 2022 Mar 4;12(3):e056431. doi: 10.1136/bmjopen-2021-056431.
8
Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.免疫检查点抑制剂治疗中静脉和动脉血栓栓塞的发生率、风险因素和结局。
Blood. 2021 Mar 25;137(12):1669-1678. doi: 10.1182/blood.2020007878.
9
Cancer associated thrombosis and mortality in patients with cancer stratified by khorana score risk levels.按 Khorana 评分风险水平分层的癌症患者的癌症相关血栓形成和死亡率。
Cancer Med. 2020 Nov;9(21):8062-8073. doi: 10.1002/cam4.3437. Epub 2020 Sep 20.
10
Assessment of adherence to cancer-associated venous thromboembolism guideline and pharmacist's impact on anticoagulant therapy.评估癌症相关静脉血栓栓塞症指南的依从性以及药师对抗凝治疗的影响。
Support Care Cancer. 2021 Mar;29(3):1699-1709. doi: 10.1007/s00520-020-05669-6. Epub 2020 Aug 10.